134 related articles for article (PubMed ID: 36174722)
1. Serum α2,6-sialylated glycoform of serotransferrin as a glycobiomarker for diagnosis and prediction of clinical severity in cholangiocarcinoma.
Kimawaha P; Thanan R; Jusakul A; Jamnongkan W; Silsirivanit A; Sa-Ngaimwibool P; Titapun A; Khuntikeo N; Sithithaworn P; Worasith C; Janthamala S; Lebrilla CB; Techasen A
Clin Chim Acta; 2022 Nov; 536():142-154. PubMed ID: 36174722
[TBL] [Abstract][Full Text] [Related]
2. Multi-serum glycobiomarkers improves the diagnosis and prognostic prediction of cholangiocarcinoma.
Silsirivanit A; Matsuda A; Kuno A; Tsuruno C; Uenoyama Y; Seubwai W; Angata K; Teeravirote K; Wongkham C; Araki N; Takahama Y; Wongkham S; Narimatsu H
Clin Chim Acta; 2020 Nov; 510():142-149. PubMed ID: 32659223
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Serotransferrin Glycoforms: Novel Markers for Diagnosis of Liver Periductal Fibrosis and Prediction of Cholangiocarcinoma.
Jamnongkan W; Lebrilla CB; Barboza M; Techasen A; Loilome W; Sithithaworn P; Khuntikeo N; Pairojkul C; Chamadol N; Thanan R; Yongvanit P
Biomolecules; 2019 Sep; 9(10):. PubMed ID: 31569686
[TBL] [Abstract][Full Text] [Related]
4. Increase of MAL-II Binding Alpha2,3-Sialylated Glycan Is Associated with 5-FU Resistance and Short Survival of Cholangiocarcinoma Patients.
Wattanavises S; Silsirivanit A; Sawanyawisuth K; Cha'on U; Waraasawapati S; Saentaweesuk W; Luang S; Chalermwat C; Wongkham C; Wongkham S
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31795149
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of the diagnostic value of Wisteria floribunda agglutinin-sialylated mucin1 and the prognostic role of mucin1 in human cholangiocarcinoma.
Tang Z; Yang Y; Wang X; Meng W; Li X
BMJ Open; 2019 Jan; 9(1):e021693. PubMed ID: 30700476
[TBL] [Abstract][Full Text] [Related]
6. A Novel Serum Glycobiomarker for Diagnosis and Prognosis of Cholangiocarcinoma Detected by
Teeravirote K; Luang S; Waraasawapati S; Boonsiri P; Wongkham C; Wongkham S; Silsirivanit A
Molecules; 2021 May; 26(9):. PubMed ID: 34066878
[TBL] [Abstract][Full Text] [Related]
7. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
8. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H
J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229
[TBL] [Abstract][Full Text] [Related]
9. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
10. Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma.
Sriwanitchrak P; Viyanant V; Chaijaroenkul W; Srivatanakul P; Gram HR; Eursiddhichai V; Na-Bangchang K
Asian Pac J Cancer Prev; 2011; 12(6):1503-10. PubMed ID: 22126489
[TBL] [Abstract][Full Text] [Related]
11. Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer.
Llop E; Peracaula R
Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
[TBL] [Abstract][Full Text] [Related]
12. Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma.
Jiang Y; Zheng X; Jiao D; Chen P; Xu Y; Wei H; Qian Y
EBioMedicine; 2019 Feb; 40():422-431. PubMed ID: 30638862
[TBL] [Abstract][Full Text] [Related]
13. [The value of CA19-9 in diagnosing hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
Chen Y; Wang ZM; Ren ZG; Le F; Zhang BH; Xia JL; Ye SL; Tang ZY
Zhonghua Gan Zang Bing Za Zhi; 2006 Apr; 14(4):299-300. PubMed ID: 16635306
[No Abstract] [Full Text] [Related]
14. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
15. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.
Banales JM; Iñarrairaegui M; Arbelaiz A; Milkiewicz P; Muntané J; Muñoz-Bellvis L; La Casta A; Gonzalez LM; Arretxe E; Alonso C; Martínez-Arranz I; Lapitz A; Santos-Laso A; Avila MA; Martínez-Chantar ML; Bujanda L; Marin JJG; Sangro B; Macias RIR
Hepatology; 2019 Aug; 70(2):547-562. PubMed ID: 30325540
[TBL] [Abstract][Full Text] [Related]
16. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis.
Köhler B; Bes M; Chan HL; Esteban JI; Piratvisuth T; Sukeepaisarnjaroen W; Tanwandee T; Thongsawat S; Mang A; Morgenstern D; Swiatek-de Lange M; Dayyani F
Int J Biol Markers; 2024 Jun; 39(2):107-117. PubMed ID: 38549363
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of GalNAcylated glycans in cholangiocarcinoma: Values for diagnosis and prognosis.
Saentaweesuk W; Silsirivanit A; Vaeteewoottacharn K; Sawanyawisuth K; Pairojkul C; Cha'on U; Indramanee S; Pinlaor S; Boonmars T; Araki N; Wongkham C
Clin Chim Acta; 2018 Feb; 477():66-71. PubMed ID: 29217428
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma and cholangiocarcinoma: an update.
Yazici C; Niemeyer DJ; Iannitti DA; Russo MW
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):63-82. PubMed ID: 24245910
[TBL] [Abstract][Full Text] [Related]
19. The association between circulating MicroRNA-150 level and cholangiocarcinoma.
Salem PES; Ghazala RA; El Gendi AM; Emara DM; Ahmed NM
J Clin Lab Anal; 2020 Nov; 34(11):e23397. PubMed ID: 33161598
[TBL] [Abstract][Full Text] [Related]
20. High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma.
Lertpanprom M; Silsirivanit A; Tippayawat P; Proungvitaya T; Roytrakul S; Proungvitaya S
Front Public Health; 2022; 10():835914. PubMed ID: 35991009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
